← Leaderboards
Amos B Smith
University Of Pennsylvania
$26,356,961
Attributed
$30,538,249
Total exposure
19
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,038,249 · 20
By mechanism
R01$20,312,444 · 9
P01$4,687,817 · 4
U01$3,109,644 · 1
P41$1,128,344 · 3
S10$1,000,000 · 2
R21$800,000 · 1
Top collaborators
- Hayley M. Mcdaid7 shared
- Cameron F Abrams6 shared
- Irwin M Chaiken6 shared
- Susan B Horwitz6 shared
- Wayne A. Hendrickson2 shared
- Joseph G Sodroski2 shared
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignProgramsLeadStructureComplexBiologicalAnalogBasePropertyLaboratoriesMolecularEvaluationInnovationProtocols DocumentationCollaborationsArchitectureBiological FactorsCellsReportingInhibitor/AntagonistProteinsAchievementMemberUnited States National Institutes Of Health
Grant awards (97)
Probing functional HIV-1 envelope glycoprotein conformations with novel potent CD4-mimetic compounds$825,965
R01 · FY2025 · AI
Novel taxane-site tubulin ligands with a dual apoptosis and senescence-inducing mechanism of action$569,502
R01 · FY2024 · CA
Antitumor Agents: Structure and Synthesis$283,582
R01 · FY2024 · CA · contact PI
Probing functional HIV-1 envelope glycoprotein conformations with novel potent CD4-mimetic compounds$889,028
R01 · FY2023 · AI
Antitumor Agents: Structure and Synthesis$296,936
R01 · FY2023 · CA · contact PI
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env Inhibitors$302,592
P01 · FY2022 · AI · contact PI
Antitumor Agents: Structure and Synthesis$289,412
R01 · FY2022 · CA · contact PI
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env Inhibitors$303,360
P01 · FY2021 · AI · contact PI
Antitumor Agents: Structure and Synthesis$293,969
R01 · FY2021 · CA · contact PI
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env Inhibitors$304,102
P01 · FY2020 · AI · contact PI
Antitumor Agents: Structure and Synthesis$292,527
R01 · FY2020 · CA · contact PI
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm$404,975
R01 · FY2019 · CA
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env Inhibitors$305,080
P01 · FY2019 · AI · contact PI
Dual-action virolytic entry inhibitors against HIV-1$469,853
R01 · FY2018 · GM
Antitumor Agents: Structure and Synthesis$293,247
R01 · FY2018 · CA · contact PI
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env Inhibitors$292,178
P01 · FY2018 · GM · contact PI
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm$221,178
R01 · FY2018 · CA
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm$196,322
R01 · FY2018 · CA
Dual-action virolytic entry inhibitors against HIV-1$469,853
R01 · FY2017 · GM
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm$417,500
R01 · FY2017 · CA
THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE CD4-GP120 ANTAGONISTS$313,367
P01 · FY2017 · GM · contact PI
Antitumor Agents: Structure and Synthesis$293,247
R01 · FY2017 · CA · contact PI
Dual-action virolytic entry inhibitors against HIV-1$50,000
R01 · FY2017 · GM
Dual-action virolytic entry inhibitors against HIV-1$469,853
R01 · FY2016 · GM
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm$413,086
R01 · FY2016 · CA
THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE CD4-GP120 ANTAGONISTS$313,367
P01 · FY2016 · GM · contact PI
Antitumor Agents: Structure and Synthesis$293,247
R01 · FY2016 · CA · contact PI
Dual-action virolytic entry inhibitors against HIV-1$96,478
R01 · FY2016 · GM
Dual-action virolytic entry inhibitors against HIV-1$490,878
R01 · FY2015 · GM
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm$429,836
R01 · FY2015 · CA
Dictyostatin and related prodrugs as candidates for tauopathy treatment$400,000
R21 · FY2015 · NS · contact PI
THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE CD4-GP120 ANTAGONISTS$312,997
P01 · FY2015 · GM · contact PI
Synthesis of Bioactive Natural Products$301,906
R01 · FY2015 · GM · contact PI
Antitumor Agents: Structure and Synthesis$293,247
R01 · FY2015 · CA · contact PI
Dictyostatin and related prodrugs as candidates for tauopathy treatment$400,000
R21 · FY2014 · NS · contact PI
THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE CD4-GP120 ANTAGONISTS$310,010
P01 · FY2014 · GM · contact PI
Synthesis of Bioactive Natural Products$302,247
R01 · FY2014 · GM · contact PI
THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE CD4-GP120 ANTAGONISTS$310,010
P01 · FY2013 · GM · contact PI
Synthesis of Bioactive Natural Products$291,987
R01 · FY2013 · GM · contact PI
Alzhelmer's Disease Drug Development Program$591,855
U01 · FY2012 · AG · contact PI
Synthesis of Bioactive Natural Products$302,898
R01 · FY2012 · GM · contact PI
Anticancer Agents: Structure and Synthesis$245,060
R01 · FY2012 · CA · contact PI
Alzhelmer's Disease Drug Development Program$609,634
U01 · FY2011 · AG · contact PI
Discovery and synthesis of small molecule CD4-gp120 antagonists$328,184
P01 · FY2011 · GM · contact PI
Anticancer Agents: Structure and Synthesis$245,551
R01 · FY2011 · CA · contact PI
Synthesis of Bioactive Natural Products$93,347
R01 · FY2011 · GM · contact PI
Alzhelmer's Disease Drug Development Program$634,310
U01 · FY2010 · AG · contact PI
Discovery and synthesis of small molecule CD4-gp120 antagonists$331,469
P01 · FY2010 · GM · contact PI
Synthesis of Bioactive Natural Products$276,075
R01 · FY2010 · GM · contact PI
Anticancer Agents: Structure and Synthesis$253,145
R01 · FY2010 · CA · contact PI
Synthesis of Bioactive Natural Products$99,000
R01 · FY2010 · GM · contact PI
Alzhelmer's Disease Drug Development Program$640,669
U01 · FY2009 · AG · contact PI
Pilot-Scale Libraries for High-throughput Screening$374,948
P41 · FY2009 · GM · contact PI
Discovery and synthesis of small molecule CD4-gp120 antagonists$325,069
P01 · FY2009 · GM · contact PI
Synthesis of Bioactive Natural Products$279,307
R01 · FY2009 · GM · contact PI
Anticancer Agents: Structure and Synthesis$253,386
R01 · FY2009 · CA · contact PI
Alzhelmer's Disease Drug Development Program$633,176
U01 · FY2008 · AG · contact PI
Pilot-Scale Libraries for High-throughput Screening$364,031
P41 · FY2008 · GM · contact PI
Discovery and synthesis of small molecule CD4-gp120 antagonists$315,621
P01 · FY2008 · GM · contact PI
Synthesis of Bioactive Natural Products$279,739
R01 · FY2008 · GM · contact PI
Anticancer Agents--Structure and Synthesis$239,298
R01 · FY2008 · CA · contact PI
Pilot-Scale Libraries for High-throughput Screening$360,272
P41 · FY2007 · GM · contact PI
Discovery and synthesis of small molecule CD4-gp120 antagonists$320,411
P01 · FY2007 · GM · contact PI
Synthesis of Spongistatin Antitumor Agents$301,935
R01 · FY2007 · CA · contact PI
Synthesis of Bioactive Natural Products$300,434
R01 · FY2007 · GM · contact PI
Anticancer Agents--Structure and Synthesis$244,369
R01 · FY2007 · CA · contact PI
2D IR OF UNUSUAL ISOTOPOMERS AND FOLDING$27,785
P41 · FY2007 · RR · contact PI
NMR SYSTEMS : 2 BRUKER AVANCE 500 CONSOLES$500,000
S10 · FY2006 · RR · contact PI
NMR systems : 2 Bruker Avance 500 Consoles$500,000
S10 · FY2006 · RR · contact PI
Synthesis of Spongistatin Antitumor Agents$305,620
R01 · FY2006 · CA · contact PI
Anticancer Agents--Structure and Synthesis$252,000
R01 · FY2006 · CA · contact PI
Synthesis of Bioactive Natural Products$55,823
R01 · FY2006 · GM · contact PI
Synthesis of Spongistatin Antitumor Agents$313,208
R01 · FY2005 · CA
Synthesis of Bioactive Natural Products$273,489
R01 · FY2005 · GM
Anticancer Agents--Structure and Synthesis$249,557
R01 · FY2005 · CA
Synthesis of Spongistatin Antitumor Agents$335,934
R01 · FY2004 · CA
Synthesis of Bioactive Natural Products$273,489
R01 · FY2004 · GM
Design and Synthesis of HIV-1 Protease Inhibitors$261,080
R01 · FY2004 · AI
Anticancer Agents--Structure and Synthesis$247,653
R01 · FY2004 · CA
SYNTHESIS OF DYE LABELED LINKERS FOR PEPTIDES$1,308
P41 · FY2004 · RR
SYNTHESIS OF SPONGISTATIN ANTITUMOR AGENTS$329,729
R01 · FY2003 · CA
Synthesis of Bioactive Natural Products$273,489
R01 · FY2003 · GM
Design and Synthesis of HIV-1 Protease Inhibitors$259,279
R01 · FY2003 · AI
Anticancer Agents--Structure and Synthesis$245,945
R01 · FY2003 · CA
SYNTHESIS OF SPONGISTATIN ANTITUMOR AGENTS$322,170
R01 · FY2002 · CA
Synthesis of Bioactive Natural Products$292,144
R01 · FY2002 · GM
Design and Synthesis of HIV-1 Protease Inhibitors$259,740
R01 · FY2002 · AI
Anticancer Agents--Structure and Synthesis$246,382
R01 · FY2002 · CA
SYNTHESIS OF SPONGISTATIN ANTITUMOR AGENTS$314,822
R01 · FY2001 · CA
Anticancer Agents--Structure and Synthesis$270,751
R01 · FY2001 · CA
Design and Synthesis of HIV-1 Protease Inhibitors$253,716
R01 · FY2001 · AI
SYNTHESIS OF CHLOROPEPTINS, GP120 CD4 BINDING INHIBITORS$220,384
R01 · FY2001 · GM
SYNTHESIS OF BIOACTIVE NATURAL PRODUCTS$77,045
R01 · FY2001 · GM
SYNTHESIS OF SPONGISTATIN ANTITUMOR AGENTS$334,698
R01 · FY2000 · CA
ANTICANCER AGENTS--STRUCTURE AND SYNTHESIS$242,879
R01 · FY2000 · CA
SYNTHESIS OF BIOACTIVE NATURAL PRODUCTS$233,867
R01 · FY2000 · GM
SYNTHESIS OF CHLOROPEPTINS, GP120 CD4 BINDING INHIBITORS$214,146
R01 · FY2000 · GM